INS and type 1 diabetes mellitus: Compared with SMBG, FSL systems have demonstrated cost effectiveness in multiple global regions and in populations of patients living with T1DM and T2DM who are using intensive insulin, as well as for those with T2DM who are using basal insulin, across both industry-sponsored and non-sponsored studies.